Curve: Microcycles made and monitored in mammalian cells

Having industrialized the cyclic peptide formation and screening methodology its CSO helped pioneer over twenty years ago,  Curve Therapeutics Ltd. is taking on transcription factors and other intracellular targets that have eluded conventional discovery approaches.

Curve co-founder and CSO Ali Tavassoli, a professor at University of Southampton, told BioCentury that a major advantage of Curve’s split intein-based discovery strategy is the variety of physiological contexts in which it can be deployed. “We’re able to generate millions of cyclic peptides in disease-relevant cells,” he said...